Compare JD.Com Inc (JD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Recursion Pharmaceuticals Inc — how do they compare? JD.Com Inc trades at $26.97 (market cap $36.51B), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: JD.Com Inc is far larger — about 15.8× Recursion Pharmaceuticals Inc's market cap, and JD.Com Inc pays a 3.7% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| JD | RXRX | |
|---|---|---|
Market Cap | $36.51B | $2.31B |
Volume | 7,051,146 | 40,478,768 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $6.79 |
52-Week Low | $25.19 | $2.84 |
Typical Hold Time | 85 Days | 22 Days |
Enterprise Value | $19.16B | $1.83B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $26.91, up 1.55% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.93 surpassing the $0.86 estimate. The company maintains robust fundamentals, including a low P/S ratio of 0.2 and a solid cash position of $234 billion as of 2024. Positive developments include potential EU approval for the $2.5 billion Ceconomy acquisition, signaling strategic expansion.
The outlook for JD.com is positive, supported by undervaluation metrics and strong free cash flow, though risks include revenue declines and regulatory scrutiny. With 69.57% of analysts rating it a Buy and a consensus price target of $35.86, the stock offers significant upside potential, but investors should monitor competitive pressures and macroeconomic headwinds in the Chinese market.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
